Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals reported Q2 2026 total revenue of $268 million, down from $452 million a year earlier, as prior-year results included a $280 million upfront payment related to a global license of sapablursen. Commercial revenue grew to $119 million, up from $103 million, driven mainly by DAWNZERA product sales and royalties from SPINRAZA and WAINUA. Product sales reached $31 million, compared with $19 million in Q2 2025.
Operating expenses rose to $370 million from $312 million, reflecting investment in launches for TRYNGOLZA and DAWNZERA and launch preparations for zilganersen. Ionis posted a GAAP net loss of $115 million versus net income of $124 million a year earlier; on a non-GAAP basis, net loss was $70 million versus non-GAAP net income of $154 million. Cash, cash equivalents and short-term investments were $2,055 million at June 30, 2026, down from $2,677 million at December 31, 2025, primarily after repayment of 0% convertible notes.
The company highlighted U.S. approval and early launch momentum for TRYNGOLZA in severe hypertriglyceridemia, DAWNZERA’s growth in hereditary angioedema, completion of enrollment in the Phase 3 REVEAL Angelman syndrome trial, and stated it remains on track to achieve its 2026 financial guidance and a goal of cashflow breakeven in 2028.
Reikes Peter N reported acquisition or exercise transactions in this Form 4 filing.
Ionis Pharmaceuticals Inc granted director Peter N Reikes 3,399 Restricted Stock Units on July 15, 2026 under its Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. The RSUs vest in three equal annual installments starting July 15, 2027 and will be fully vested on July 15, 2029. Following this award, Reikes holds 3,399 RSUs directly, all unvested as of the grant date.
HANTSON LUDWIG reported acquisition or exercise transactions in this Form 4 filing.
Ionis Pharmaceuticals director Ludwig Hantson received a grant of 3,399 Restricted Stock Units on July 15, 2026 under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Each RSU is a contingent right to one share of common stock or its cash value, vesting in three equal annual installments from July 15, 2027 and fully vesting on July 15, 2029. As of the grant date, 0 RSUs were vested and he holds 3,399 RSUs in total.
Ionis Pharmaceuticals director Joan E. Herman reported the vesting of 5,220 Restricted Stock Units on July 15, 2026, which were settled into 5,220 shares of common stock at $0.0000 per share. Following this derivative exercise, she directly holds 51,306 common shares and 2,301 Restricted Stock Units.
IONIS PHARMACEUTICALS director Spencer R. Berthelsen reported vesting of 5,220 Restricted Stock Units on July 15, 2026, converting into the same number of common shares at no cost. After this conversion, he directly holds 161,233 common shares and 2,301 RSUs. An additional 70 common shares are held indirectly by his daughter, for which he disclaims beneficial ownership.
Ionis Pharmaceuticals, Inc. reaffirmed its previously announced financial guidance for the fiscal year ending December 31, 2026. The outlook remains unchanged from the financial guidance communicated on April 29, 2026 in its first quarter 2026 earnings release.
The company characterizes these expectations as forward-looking statements that involve risks and uncertainties related to discovering, developing and commercializing human therapeutics and building a business around them. It notes that actual results could differ materially if underlying assumptions do not materialize, and directs readers to its annual report for the year ended December 31, 2025 and its most recent quarterly report for a more detailed description of risks.
Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett reported insider transactions involving company stock. On July 7, he executed open-market sales of 15,000 shares held indirectly through a trust at a weighted average price of $85.462 per share and 5,536 shares held directly at a weighted average price of $83.579 per share, under a pre-arranged Rule 10b5-1 trading plan. He also transferred 15,000 shares from direct to indirect ownership via a family trust and reported 15,000 restricted stock units that vested on January 15, 2026 and were paid in common shares. Following these transactions, he holds 75,018 shares directly, 15,000 shares indirectly through the trust, and 12,109 restricted stock units.
Ionis Pharmaceuticals director Allene M. Diaz exercised stock options and then sold the resulting shares. On July 7, 2026, Diaz exercised a non-qualified stock option to acquire 10,111 shares of common stock at $47.11 per share, then sold 10,111 shares in open-market transactions at a weighted average price of $85.4156 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Diaz directly owned 3,811 shares of Ionis common stock.
IONIS PHARMACEUTICALS INC EVP and Chief Development Officer Holly B. Kordasiewicz sold 362 shares of common stock in an open-market transaction at $84.30 per share on July 7, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, and she now holds 22,096 shares directly.
Ionis Pharmaceuticals reported that the CARDIO-TTRansform Phase 3 trial of eplontersen in transthyretin-mediated amyloid cardiomyopathy did not meet its primary endpoint, a composite of cardiovascular death and recurrent cardiovascular events through Week 140 versus placebo.
In patients receiving contemporary standard of care, including many on TTR stabilizers, adding eplontersen did not show a statistically significant benefit on this main outcome. A prespecified subgroup on eplontersen monotherapy showed a nominally significant hazard ratio of 0.71 for the same composite. Secondary imaging and biomarker measures generally favored eplontersen, and the drug showed large, sustained reductions in transthyretin with a safety profile consistent with prior studies. Ionis and AstraZeneca plan to present full results at the European Society of Cardiology Congress in August 2026.